Adverum Biotechnologies Expands Leadership Team with the Appointment of Peter Soparkar as Chief Legal Officer
“We are pleased to welcome Peter to our leadership team as he brings deep legal and organizational experience,” said
Mr. Soparkar commented, “I’m excited to join Adverum at this pivotal time for the company. I look forward to working with the team to maximize Adverum’s potential of becoming a leader in the gene therapy space, focusing on developing new therapy options for patients with serious ocular and rare diseases.”
Mr. Soparkar has over 15 years of legal experience, including corporate development, corporate governance, legal, regulatory, commercial, and public compliance activities, for biotechnology companies as well as at a leading international law firm. Prior to joining Adverum, Mr. Soparkar was chief legal officer and head of human resources at
On the date Mr. Soparkar commenced employment with Adverum, the company granted Mr. Soparkar a stock option to purchase 400,000 shares of Adverum’s common stock pursuant to the inducement grant exception under Nasdaq Rule 5635(c)(4), as an inducement that is material to his entering into employment with Adverum. The option has a per share exercise price equal to the closing sales price of Adverum’s common stock on the Nasdaq Stock Market on the grant date, and will vest over four years, subject to his continued service with Adverum.
About Adverum Biotechnologies, Inc.
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. For more information, please visit www.adverum.com.
Investor and Media Inquiries:
Vice President, Investor Relations and Corporate Communications
Cherilyn Cecchini, M.D.
Source: Adverum Biotechnologies, Inc.